Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - betamethasone valerate - cutaneous cream - 1mg/1gram

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - betamethasone valerate - cutaneous cream - 1mg/1gram

Storbritannia - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

manx healthcare ltd - betamethasone valerate - cutaneous cream - 1mg/1gram

USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - betamethasone valerate 1.2 mg in 1 g - luxíq is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. luxíq is contraindicated in patients who are hypersensitive to betamethasone valerate, to other corticosteroids, or to any ingredient in this preparation.

Hellas - gresk - Εθνικός Οργανισμός Φαρμάκων

mylan ireland limited, ireland unit 35/36 grange parade, - dublin 13 - fusidic acid; betamethasone valerate - cream (ΚΡΕΜΑ) - (20+1)mg/g - fusidic acid 20mg; betamethasone valerate 1,214mg - betamethasone and antibiotics

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - betamethasone valerate, quantity: 1.22 mg/g (equivalent: betamethasone, qty 1 mg/g) - ointment - excipient ingredients: liquid paraffin; white soft paraffin - indications as at 23 april 2004 : eczema including : atopic, infantile, stasis and discoid eczemas. besnier's (flexural) prurigo. otitis externa. neurodermatoses including lichen simplex, lichen planus. seborrheic dermatitis, contact sensitivity reactions and allergies.

Kypros - gresk - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

pharmascience international ltd (0000011496) lampousas 1, nicosia, 1095 - fusidic acid; betamethasone valerate - cream - (20mg/1mg)/g - fusidic acid (8000002385) 20mg; betamethasone valerate (0002152445) 1mg - betamethasone and antibiotics

USA - engelsk - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

USA - engelsk - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

USA - engelsk - NLM (National Library of Medicine)

a-s medication solutions - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hpa axis suppression and cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. hypothalamic-pituitary-adrenal (hpa) axis suppression, cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. chronic corticosteroid therapy may interfere with the growth and development of children.